Mesoblast Limited (MSB) is an Australian biotechnology
company involved in the development of novel treatments for
orthopaedic conditions, including the commercialisation of a
unique adult stem cell technology aimed at the regeneration
and repair of bone and cartilage. During fiscal year 2008,
Mesoblast remained on track to achieve its goals for
commercialising our unique adult stem cell technology platform.